Comparative Pharmacology
Head-to-head clinical analysis: KETEK versus NEO RX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KETEK versus NEO RX.
KETEK vs NEO-RX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Telithromycin binds to the 50S subunit of bacterial ribosome, inhibiting protein synthesis by blocking peptide chain elongation.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis in susceptible bacteria.
Telithromycin 800 mg orally once daily for 7-10 days.
100 mg intravenously every 12 hours.
None Documented
None Documented
Terminal half-life (t½) is 9.8–10.6 hours in young healthy adults, allowing once-daily dosing. In elderly or severe hepatic impairment, t½ may be prolonged.
Terminal elimination half-life is 2.5-3 hours in adults with normal renal function; increased to up to 10-15 hours in severe renal impairment (CrCl <30 mL/min). Clinically, this supports 8-hourly dosing intervals in normal renal function, with extended intervals in renal impairment.
Primarily fecal (≈70%) via biliary excretion of unchanged drug; renal excretion accounts for ≈13% (mostly unchanged), with additional minor metabolism (<30%).
Renal excretion accounts for 90-100% of elimination, primarily as the parent drug via glomerular filtration and tubular secretion. Urinary excretion: 90-100% unchanged. Fecal/biliary: negligible (<2%).
Category C
Category C
Antibiotic, Ketolide
Antibiotic